Skip to content
value.today
MacroGenics Inc. logo

MacroGenics Inc.

Total raised
$12 M
1 round on record
Latest round
$12 M
Jan 2011
First round on record
Jan 2011
Today
Went public
See the company page

MacroGenics Inc. is listed today as MacroGenics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of MacroGenics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2011$12 MNo. 1$10 to $50 million

MacroGenics Inc.: Raise no. 1, Jan 2011

Investors in this round

3 investors had bought by the notice of Jan 31, 2011: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for MacroGenics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Karrels · Executive Officer
  • Scott Koenig · Executive Officer, Director
  • Arnold Oronsky · Director
  • Ed Hurwitz · Director
  • Ken Galbraith · Director
  • Michael Steinmetz · Director
  • Paul Sekhri · Director
  • Paulo Costa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The proceeds from the offering will be used for general working capital purposes.”

Signed by James Karrels, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 31, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company MacroGenics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaborative and other agreements $87.18 million (58%), Contract manufacturing $52.63 million (35%), Royalty revenue $9.69 million (6%).

    Annual report (SEC XBRL) · Dec 2025

  • MacroGenics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2011).

    SEC Form D · Jan 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2011

Products and services#

No products or services of MacroGenics Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in MacroGenics Inc.
InvestorKindAmountRoundRoleSource
Alta Biopharma Partners III Gmbh & Co Beteiligungs KGFund or asset managernot statednot statedHeld Series B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Alta Biopharma Partners III LPFund or asset managernot statednot statedHeld Series B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Alta Embarcadero Biopharma Partners III LLCFund or asset managernot statednot statedHeld Series B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Interwest Investors Q VIII LPFund or asset managernot statednot statedHeld Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Interwest Investors VIII L.P.Fund or asset managernot statednot statedHeld Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
InterWest Management Partners VIII, LLCFund or asset managernot statednot statedHeld Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Interwest Partners VIII LPFund or asset managernot statednot statedHeld Series A-1, B, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3
TPG Group Holdings (SBS) Advisors, Inc.Fund or asset managernot statednot statedHeld Series B-1, C and D-2 preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 3 investors.

Largest shareholders today

Institutions holding MacroGenics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by MacroGenics Inc.
NameRoleNamed in
James KarrelsExecutive officerJan 2011
Scott KoenigExecutive officerJan 2011
Arnold OronskyDirectorJan 2011
Ed HurwitzDirectorJan 2011
Ken GalbraithDirectorJan 2011
Michael SteinmetzDirectorJan 2011
Paul SekhriDirectorJan 2011
Paulo CostaDirectorJan 2011
Scott KoenigDirectorJan 2011

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.